Home›Signals›Clinical Trial Activity
■

Clinical Trial Activity

Active clinical trials by phase and status

50 Active Signals
KYTXKyverna Therapeutics, Inc.Cell Therapy
A
85/100
IBRXImmunityBio, Inc.Biotech / Pharma
C
64/100
SYNHSyneos HealthCRO Biopharmaceutical
A
91/100
XENEXenon PharmaceuticalsIon Channel CNS
B
78/100
SWTXSpringWorks TherapeuticsRare Oncology
A
91/100
ASNDAscendis PharmaRare Endocrine
B
71/100
RIGLRigel PharmaceuticalsImmunology
B
69/100
IDYAIDEAYA BiosciencesPrecision Oncology
C
62/100
ITCIIntra-Cellular TherapiesNeuroscience
B
68/100
RVMDRevolution MedicinesPrecision Oncology
C
65/100
RGNXREGENXBIO IncGene Therapy
B
66/100
AXSMAxsome TherapeuticsNeuroscience
C
62/100
DCPHDeciphera PharmaceuticalsOncology
A
91/100
UTHRUnited TherapeuticsPulmonary
B
73/100
INCYIncyte CorporationOncology
B
69/100
BMRNBioMarin PharmaceuticalRare Disease
B
75/100
YMABY-mAbs TherapeuticsPediatric Oncology
A
91/100
KPTIKaryopharm TherapeuticsOncology
A
87/100
RCUSArcus BiosciencesImmuno-Oncology
C
59/100
ARVNArvinas IncProtein Degradation
B
66/100
SRPTSarepta TherapeuticsGene Therapy
A
86/100
SGENSeagen IncOncology ADC
A
91/100
AMGNAmgen IncBiologics
B
75/100
MRNAModerna IncmRNA Therapeutics
D
41/100
JAZZJazz Pharmaceuticals plcBiotech / Pharma
C
63/100
SMMTSummit Therapeutics Inc.Biotech / Pharma
C
62/100
ISRGIntuitive Surgical, Inc.Biotech / Pharma
F
14/100
UCBNVUCB SANeurology Immunology
C
61/100
ICLRICON plcCRO Clinical Research
C
59/100
DXCMDexCom IncDiabetes Tech
F
25/100
SNDXSyndax PharmaceuticalsOncology
C
58/100
ARWRArrowhead PharmaceuticalsRNAi Therapeutics
C
56/100
MIRMMirum PharmaceuticalsLiver Disease
C
51/100
ARGXargenx SEAutoimmune
C
55/100
NVONovo NordiskDiabetes/Obesity
C
51/100
BAYRYBayer AGPharma/Crop Science
C
60/100
SNYSanofi SAImmunology
C
52/100
NVSNovartis AGDiversified Pharma
C
52/100
AZNAstraZenecaOncology/Respiratory
C
53/100
MRKMerck & CoOncology/Vaccines
C
57/100
PFEPfizer IncDiversified Pharma
D
44/100
JNJJohnson & JohnsonDiversified Pharma
D
38/100
LLYEli Lilly and CompanyDiabetes/Oncology
D
43/100
BMYBristol-Myers SquibbOncology
D
41/100
BGNEBeiGene LtdOncology
A
88/100
TGTXTG TherapeuticsOncology
C
61/100
GRFSGrifols SAPlasma Therapeutics
C
52/100
IMVTImmunovant IncAutoimmune
C
64/100
ARQTArcus BiosciencesImmuno-Oncology
C
59/100
ALNYAlnylam PharmaceuticalsRNAi Therapeutics
C
53/100
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.